Table 1 Characteristics at ART start by gender patients initiated on standard first line antiretroviral therapy at the Infectious Diseases Institute Kampala, Uganda
From: Reasons for first line ART modification over the years during the ART scale up in Uganda
Characteristics | Overall N = 14,261 (100%) | Female N = 9114 (63.9%) | Male N = 5147 (36.1%) | P value |
|---|---|---|---|---|
Age in completed years, median (IQR) | 36 (30–42) | 34 (29–40) | 38 (33–44) | < 0.001 |
WHO stage 3 and 4, n (%) | 7749 (60.8) | 4533 (55.8) | 3216 (69.7%) | < 0.001 |
BMI, kg/m2, median, (IQR) n (%)a | 21.9 (19.6–24.8) | 22.7 (20.1–25.8) | 20.8 (19–22.9) | < 0.001 |
 Underweight (< 18.5) | 1975 (14.7) | 1037 (12.1) | 938 (19.4) | < 0.001 |
 Normal (18.5–25) | 8231 (64.4) | 4926 (57.5) | 3305 (68.4) |  |
 Overweight (> 25) | 3196 (23.9) | 2604 (30.4) | 592 (12.24) | |
CD4 count, cells/µL, median (IQR)b | < 0.001 < 0.001 | |||
 n (%) | 188 (65–353) | 210 (80–380) | 153 (47–300) | |
 < 200 cells/µL | 7274 (52.2) | 4317 (48.2) | 2957 (59.3) | |
 200–350 cells/µL | 3139 (22.5) | 2094 (23.4) | 1045 (21) |  |
 > 350 cells/µL | 3519 (25.3) | 2537 (28.4) | 982 (19.7) |  |
Period of ART start, n (%) | 0.682 | |||
 2005–2008 | 6879 (48.2) | 4408 (48.4) | 2471 (48.0) | |
 2009–2017 | 7382 (51.8) | 4706 (51.6) | 2676 (52.0) | |
ART regimen n, (%) | 0.007 | |||
 Stavudine | 3932 (27.5) | 2565 (28.2) | 1367 (25.6) | |
 Zidovudine | 6555 (46.0) | 4213 (46.2) | 2342 (45.5) | |
 Tenofovir | 3774 (26.5) | 2336 (25.6) | 1438 (27.9) | |